immunotherapies

Aug 05, 2026

Summary Intra-tumoral cancer therapies involve the direct administration of antitumor agents into tumors, promoting localized tumor destruction, stimulating the release of tumor-associated antigens, and activating an immune response within the tumor microenvironment that may also generate systemic antitumor eff...

Jun 12, 2026

Pfizer's USD 10.5 billion partnership with Innovent Biologics is not just another oncology deal; it is a strategic masterstroke in Pfizer's bid to dominate cancer therapy. In May 2026, Pfizer and Innovent announced a global collaboration covering 12 early-stage and de novo oncology programs, including next-generati...

Feb 02, 2021

Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...